Digitisation | December 30, 2023
Qure solidifies its position as innovation powerhouse with 26 patents
Marks remarkable acceleration in innovation using AI technology
Marks remarkable acceleration in innovation using AI technology
The company has received marketing authorisation for docetaxel from Israel and cytarabine from Colombia
Loteprednol Etabonate Ophthalmic Suspension, 0.2%, is indicated for the temporary relief of the signs and symptoms of seasonal allergic conjunctivitis
The product is expected to be launched in December 2023
US FDA approval based on NEURO-TTRansform Phase III results
Furthering cell therapy ambition across oncology and autoimmune diseases
If approved, Xolair would be the first medicine to reduce allergic reactions to multiple foods following an accidental exposure
The plant is yet to start commercial operations
Funding round led by Sarissa Capital, includes Sun Pharma, Polaris Partners
Transaction delivers KarXT, a first-in-class M1/ M4 muscarinic receptor agonist with differentiated efficacy and safety
Subscribe To Our Newsletter & Stay Updated
